Effects of ABT-089 on Smoking Abstinence Symptoms and Reward
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Nicotine Addiction
In brief
This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089 (an experimental medication not approved by the FDA) when administered as 40mg oral once daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive deficits, smoking withdrawal, smoking urges, smoking reward, and a brief, monitored quit attempt (\~4 days). The key cognitive domains include: working memory, sustained attention, and response inhibition.
Key facts
- Study ID
- NCT01756053
- Run by
- University of Pennsylvania
- People needed
- 17
- Starts
- 2013-03-01
- Expected to finish
- 2014-01-01
- Last updated by the study team
- 2014-10-29
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Center for Interdisciplinary Research on Nicotine Addiction, University of Pennsylvania — Philadelphia, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.